report presents a case of nasopharyngeal diffuse large B-cell lymphoma and a literature review concerning the use of [ 18 F]fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). A 37-year old man was admitted to hospital complaining of nasal secretions with minor epistaxis and a 20year history of snoring. Nasal endoscopy found diffuse swelling in the nasopharynx and a biopsy was performed. Prior to chemotherapy, FDG-PET/CT showed softtissue diffuse thickening and FDG accumulation in the nasopharynx and bilateral cervical lymph nodes; FDG did not accumulate elsewhere. After four cycles of chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine) and prednisone treatment, FDG-PET/CT showed that FDG still accumulated in the nasopharynx and bilateral cervical lymph nodes, therefore radiotherapy was initiated. At 1 year, FDG-PET/CT showed no FDG accumulation. Immunohistochemical analysis revealed that the tumour was positive for phosphorylated protein kinase B (Akt), suggesting that FDG uptake may be associated with factors activated by the phosphatidylinositol 3-kinase/Akt signalling pathway.
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Introduction
Metabolic changes occur before morphological changes in malignant cells, 1 therefore diagnostic tools that can detect metabolic changes are important in the early identification of malignancy. Malignant cells take up and use more glucose than normal cells 2 and positron emission tomography/computed tomography (PET/CT), using [ 18 F]fluorodeoxyglucose (FDG), has been used to detect both primary 3 and metastatic tumours. 4 Since 1987, when an increase in FDG uptake in lymphoma was found, 5 many reports have revealed the clinical usefulness of FDG-PET for tumour detection 6 and accurate staging, management and monitoring of subsequent treatment response 7 in lymphoma.
A previous study revealed that FDG uptake was higher in malignant lymphoma than in other head and neck malignant tumours, as measured by single photon emission CT, and a significant correlation was found between FDG levels and glucose transporter (Glut)-1 mRNA or protein levels. 8 The real determinant of high FDG uptake in malignant tumours including lymphoma is, however, uncertain. 8, 9 In lymphoma, there are few studies on the mechanism of FDG uptake. 9 -11 To our knowledge, there is no previous report on the correlation between FDG uptake and the phosphatidylinositol 3kinase and protein kinase B (PI3K/Akt) signal transduction pathway in lymphoma.
Here, a case of nasopharyngeal diffuse large B-cell lymphoma (DLBCL) is reported, and the usefulness of FDG-PET/CT for tumour staging and monitoring the response to a chemotherapy regime consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) and radiotherapy is analysed. The presence of Glut-1, Glut-3, hypoxia-inducible factor-1α (HIF-1α), PI3K and phosphorylated Akt proteins, and their relationship to FDG uptake in B-cell lymphomas, was also investigated.
Approval for the study was obtained from the Institutional Review Board of The First Affiliated Hospital, College of Medicine, Zhejiang University (Hangzhou, China) and the patient gave consent for the details of his case to be published.
Case report
A 37-year old man was admitted to the Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, on 24 November 2008, with a 20-year history of snoring, a 2-month history of sleep apnoea and a 1-month history of nasal secretions with minor epistaxis. The patient denied irritability, short temper, morning headache or forgetfulness. He had been shown to have sleep apnoea and daytime sleepiness 2 months previously and he had no history of difficulty in breathing. His past medical history was not significant.
In October 2008, polysomnography demonstrated an apnoea-hypopnoea index of 80/h with the lowest oxyhaemoglobin saturations being 70%. The patient was diagnosed with severe obstructive sleep apnoea-hypopnoea syndrome. Examination of the ears, nose and throat revealed an obstructive oropharynx. There was no mass in the neck, nasopharynx or larynx. The patient was advised to undergo uvulopalatopharyngoplasty and pre-operative treatment with continuous positive airway pressure.
On 20 November 2008, the patient complained of a painless mass in the left side of his neck. Nasal endoscopy found diffuse swelling in the nasopharynx, and a biopsy of the nasopharynx was performed. The patient fasted for at least 6 h before FDG-PET/CT studies were undertaken, prior to chemotherapy. FDG-PET/CT showed softtissue diffuse thickening and FDG accumulation in the nasopharynx and increased FDG in the cervical lymph nodes, bilaterally; other parts did not reveal any increased FDG uptake ( Fig. 2 ). Stage II extranodular non-Hodgkin's lymphoma (nasopharyngeal DLBCL) was diagnosed.
On 26 November 2008, the patient received the first cycle of the R-CHOP chemotherapy regimen. He was treated with rituximab (600 mg/m 2 , intravenously [i.v.]) on day 1 of each cycle of R-CHOP, according to standard prescribing guidelines. 12 The R-CHOP regimen included cyclophosphamide (0.8 g/m 2 , i.v., day 1), epirubicin (90 mg/m 2 , i.v., day 1), vincristine (1.4 mg/m 2 , i.v., day 1), and prednisone (40 mg/m 2 per day, orally, days 1 -5). The patient was treated every 4 weeks.
After four cycles of R-CHOP treatment, At the 1-year follow-up, the patient was reexamined by FDG-PET/CT. The result showed no FDG accumulation in the body, except for normal physiological areas of absorption ( Fig. 3) .
To study the possible cause of the increased FDG uptake, the presence of Glut-1, Glut-3, PI3K, HIF-1α and Akt proteins in the biopsied nasopharyngeal tissue was investigated by immunohistochemistry using an EliVision™ Plus kit (Maixin Biological) according to the manufacturer's instructions. Tissue samples were formalinfixed and paraffin-embedded. The immunostaining procedure used has been previously. 13 Briefly, the antibodies, dilutions, antigen-retrieval methods and sources are detailed in Table 1 . Antigen retrieval was performed after the sections were deparaffinized with xylene and dehydrated through an ethanol series. Endogenous peroxidase activity was blocked by incubating the slides in 1.5% hydrogen peroxide in absolute methanol at room temperature for 10 min. Primary antibodies were applied for 1 h at room temperature, followed by 50 µl of polymer enhancer for 20 min and 50 µl of polymerized horseradish peroxidise-antimouse immunoglobulin G for 30 min, both at room temperature. Tissue sections were washed three times with 0.05 mol/l Tris-buffered saline (TBS), pH 7.2, at each step. The reaction products were visualized using diaminobenzidine (DAB kit; Maixin Biological) and the sections were Immunohistochemical analysis of the present case showed that the tumour was positive for CD20 ( Fig. 1B) and Akt (Fig. 4) , but negative for Glut-1, Glut-3, HIF-1α and PI3K protein.
Discussion
Besides its established role as a diagnostic technique, PET/CT has an expanding role as a method for assessing the response to therapy, in particular to cancer therapy. 2 -7 There are now over 80 PET/CT centres in China, although limitations to the The present study reports on a patient with DLBCL in the nasopharynx, which is a rare condition. To our knowledge, there have been no previous reports using PET/CT in DLBCL of the nasopharynx. Although negative FDG accumulation has been reported in some patients with LBCL, 14 there are many more LBCL cases with increased FDG uptake. 15, 16 In the present case, FDG accumulation was seen only in the nasopharynx and bilateral cervical lymph nodes, which provided the staging basis for a 
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diagnosis of DLBCL. FDG-PET/CT has also been introduced to assess the treatment response of various malignant tumours and to detect recurrent tumours; 7, 11 in this present case, it was also found that PET/CT could be used to monitor the therapeutic response to R-CHOP and radiotherapy and, thereby, help to determine the patient's prognosis.
[ 18 F]Fluorodeoxyglucose accumulation is a common phenomenon in lymphomas; however, the underlying biological mechanism of increased FDG uptake in lymphomas remains unknown, and there are few studies on the mechanism of this uptake. 9 -11 The effect of Glut-1 in FDG uptake is controversial. Usually, in malignant tumour cells, Glut-1 is the major protein mediating the specific transport of FDG. 8 Koga et al. 11 revealed that FDG accumulation was associated with Glut-1 protein. In contrast, Shim et al. 9 found that Glut-1 played no role in FDG uptake in B-cell non-Hodgkin's lymphoma, but that hexokinase-II (HK-II) and Glut-3 contributed significantly to FDG uptake in DLBCL. In Reed-Sternberg cells, high levels of Glut-1 played a key role in high FDG uptake in Hodgkin's lymphoma, but there was no specific correlation between the presence of Glut-3 and HK-II proteins and FDG uptake. 10 No Glut-1 or Glut-3 protein was found in the nasopharyngeal DLBCL in the present study. Thus, we suggest that FDG uptake had no apparent relationship with Glut-1 or Glut-3 in this case.
In some malignant tumours, high FDG uptake has been associated with factors activated by the PI3K/Akt signalling pathway, 17, 18 which is a plausible candidate for mediating the enhancement of FDG uptake. 17, 19 Prante et al. 17 found that thyroidstimulating hormone-induced FDG uptake is primarily mediated through the PI3K pathway in FRTL-5 cells. PI3K/Akt is not only a wellrecognized regulator of cell growth, survival and angiogenesis, but it also plays an important role in promoting glucose metabolism. 18, 19 Oncogenic factors, including c-Myc, 20 Akt, 21 and HIF-1α, 22 have been implicated in regulating aerobic glycolysis. Phosphorylated Akt can stimulate HIF-1α, and HIF-1α can inhibit the transactivation activity of c-Myc. 23 Kaira et al. 24 found that FDG uptake in thymic epithelial tumours was determined by the presence of HIF-1α. Others have, however, demonstrated that FDG uptake was not related to HIF-1α in thyroid cancer, 25 breast cancer 26 and pulmonary pleomorphic carcinoma. 27 To our knowledge the present report is the first to explore the correlation between FDG uptake and phosphorylated Akt, PI3K, HIF-1α and Glut-1 protein in lymphoma. Although there were no relationships between FDG accumulation and Glut-1, Glut-3 or HIF-1α proteins in this case of DLBCL, the tumour was positive for phosphorylated Akt and there was a relationship between phosphorylated Akt positivity and high FDG accumulation. These results indicate that other factors may play a role in FDG uptake. Ahn et al. 18 revealed that HK-II played an important role in FDG uptake by both the PI3K-dependent and PI3K-independent Akt signalling pathways. Thus, the role of HK-II should be further investigated.
In conclusion, DLBCL in the nasopharynx is rare. FDG-PET/CT can provide the basis for staging and for monitoring the therapeutic response to R-CHOP and radiotherapy, and can help in determining the patient's prognosis. The underlying biological mechanism of increased FDG uptake in lymphoma remains unknown, although Akt may be a determining factor for high FDG uptake in lymphomas.
